CTLA4 and melanoma: Given CTLA-4 complex mechanism on the immune system, inhibiting CTLA-4 action might enhance immunosurveillance, and first antibody against CTLA-4, ipilimumab, which can bind both mCTLA-4 and sCTLA-4, was approved in 2011 for the treatment of melanoma [27].